Related Experiment Video
Updated: Jul 8, 2026
04:37
Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
Published on: June 6, 2025
Doxazosin for benign prostatic hyperplasia: an open-label, baseline-controlled study in Korean general practice
Byung Ha Chung1, Sung Joon Hong, Moo Sang Lee
1Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea. Chung646@yumc.yonse.ac.kr
Summary
Doxazosin effectively treated symptomatic benign prostatic hyperplasia (BPH) in Korean men, significantly improving International Prostate Symptom Score (IPSS) and related symptoms with manageable side effects.
Area of Science:
- Urology
- Pharmacology
- Clinical Trials
Background:
- Limited research exists on benign prostatic hyperplasia (BPH) treatment in Asian populations.
- Assessing doxazosin, a selective alpha1-adrenoceptor antagonist, for Korean patients with symptomatic BPH.
Purpose of the Study:
- To evaluate the safety and efficacy of doxazosin in treating symptomatic benign prostatic hyperplasia (BPH).
- To assess doxazosin's impact on International Prostate Symptom Score (IPSS) in a Korean population.
Main Methods:
- A 12-week, open-label, multicenter study involving 295 men aged 48+ with BPH.
- Dose titration of doxazosin (1-8 mg/day) after a 2-week placebo run-in.
- Efficacy assessed using the International Prostate Symptom Score (IPSS) at multiple time points.
Main Results:
- Doxazosin significantly reduced mean total IPSS by 48% (P < 0.001).
- Obstructive and irritative subscores decreased by 51% and 39%, respectively.
- Adverse events like dizziness and dyspepsia were reported by 39 patients.
Conclusions:
- Doxazosin demonstrated efficacy and safety in treating BPH in this Asian cohort.
- Significant improvements in overall, obstructive, and irritative BPH symptoms were observed.
